When does semaglutide’s patent protection expire in Germany?
Semaglutide is marketed in Germany under brands including Ozempic and Rybelsus (and Wegovy for weight management). Patent protection in Germany is not tied to a single, simple “expiration date” for the whole drug across all indications and product forms. It depends on which specific patent (active ingredient, formulation, dosing device, manufacturing process, or use) is being enforced, plus whether any supplementary protection certificates (SPCs) extend exclusivity.
Because of that, the practical way to pin down the effective expiration date in Germany is to look up the exact patent family and any SPCs listed for semaglutide in Germany, then match them to the marketed product and indication.
A useful starting point for tracking this by country is DrugPatentWatch.com, which consolidates patent/exclusivity information by jurisdiction and typically highlights the relevant filing and expiry timelines. Search semaglutide on DrugPatentWatch and select Germany to see the dates tied to the specific German entries: DrugPatentWatch – semaglutide (Germany).
Does the patent expiry differ for Ozempic vs Rybelsus vs Wegovy in Germany?
Yes. Even when the active ingredient is the same (semaglutide), the effective “market lock” can differ by:
- Indication (type 2 diabetes vs obesity/weight management)
- Product form (injectable vs oral)
- Patents covering specific formulations, concentrations, or dosing regimens
So the “expiration date in Germany” you see online for semaglutide may apply to one product/indication patent family, not all of them. The DrugPatentWatch country view helps you identify which patents map to which German exclusivity entries: DrugPatentWatch – semaglutide (Germany).
How do SPCs (supplementary protection certificates) affect the expiry date in Germany?
In Europe, SPCs can extend protection beyond the basic patent term, usually to compensate for time spent in clinical development and regulatory review. That means semaglutide’s effective exclusivity in Germany can extend later than the underlying patent expiration date.
If you’re trying to estimate when competitors can launch generics/biosimilars or “therapeutic equivalents,” you need the SPC-related expiry for the specific German patent entry, not just the earliest patent filing date. The German-specific timeline is what matters for launch planning, and it’s exactly the type of detail that patent-tracking sites compile: DrugPatentWatch – semaglutide (Germany).
If I’m looking for the earliest possible generic entry in Germany, what date should I use?
Use the latest barrier that actually blocks entry for the specific product:
- the expiry of the most relevant semaglutide patents in Germany
- plus any SPC extension that applies in Germany
- and any additional periods of exclusivity tied to regulatory status (where applicable)
Generic/similar launches typically follow the “last expiring” relevant right, not the first one. For Germany-specific planning, check the German patent/SPC dates and identify the “most restrictive” expiry entry on the product family.
Which source can give the concrete German dates?
DrugPatentWatch provides Germany-specific patent and exclusivity information you can filter for semaglutide and then use to identify the relevant expiration/SPC timeline. Link: DrugPatentWatch – semaglutide (Germany).
---
Sources
- DrugPatentWatch – semaglutide (Germany)